Advanced Glycation End Products and Diabetic Retinopathy
Advanced Glycation End Products and Diabetic Retinopathy
复制标题
DOI：
10.2174/09298673113209990025
复制
发表时间：
2013-09-01
影响因子：
4.1
通讯作者：
Stitt, A. W.
中科院分区：
文献类型：
--
作者：
Chen, M.;Curtis, T. M.;Stitt, A. W.
糖尿病视网膜病变 (DR) 具有复杂的发病机制，受到糖尿病环境引起的一系列系统异常和组织特异性改变的影响。许多致病过程在糖尿病患者的视网膜损伤中发挥着关键作用。其中一种途径是晚期糖基化终产物（AGE）和晚期脂氧化终产物（ALE）的形成和积累，它们是在病理学的起始和进展中发挥作用的相关修饰。在这篇综述中，讨论了糖尿病视网膜中 AGE/ALE 的形成及其对视网膜细胞功能的影响。此外，还将评估AGE-RAGE系统的各种抑制剂及其对DR的治疗效用。
Diabetic retinopathy (DR) has a complex pathogenesis which is impacted by a raft of systemic abnormalities and tissue-specific alterations occurring in response to the diabetes milieu. Many pathogenic processes play key roles in retinal damage in diabetic patients. One such pathway is the formation and accumulation of advanced glycation endproducts (AGEs) and advanced lipoxidation end products (ALEs) which are relevant modifications with roles in the initiation and progression of pathology. In this review, AGE/ALE formation in the diabetic retina is discussed alongside their impact on retinal cell function. In addition, various inhibitors of the AGE-RAGE system and their therapeutic utility for DR will also be evaluated.